154 related articles for article (PubMed ID: 17339423)
1. Heparanase influences expression and shedding of syndecan-1, and its expression by the bone marrow environment is a bad prognostic factor in multiple myeloma.
Mahtouk K; Hose D; Raynaud P; Hundemer M; Jourdan M; Jourdan E; Pantesco V; Baudard M; De Vos J; Larroque M; Moehler T; Rossi JF; Rème T; Goldschmidt H; Klein B
Blood; 2007 Jun; 109(11):4914-23. PubMed ID: 17339423
[TBL] [Abstract][Full Text] [Related]
2. Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.
Mahtouk K; Cremer FW; Rème T; Jourdan M; Baudard M; Moreaux J; Requirand G; Fiol G; De Vos J; Moos M; Quittet P; Goldschmidt H; Rossi JF; Hose D; Klein B
Oncogene; 2006 Nov; 25(54):7180-91. PubMed ID: 16732320
[TBL] [Abstract][Full Text] [Related]
3. Role of Heparanase and Syndecan-1 in HSV-1 Release from Infected Cells.
Sharma P; Kapoor D; Shukla D
Viruses; 2022 Sep; 14(10):. PubMed ID: 36298711
[TBL] [Abstract][Full Text] [Related]
4. The Uptake of Heparanase into Mast Cells Is Regulated by Its Enzymatic Activity to Degrade Heparan Sulfate.
Shi J; Onuki Y; Kawanami F; Miyagawa N; Iwasaki F; Tsuda H; Takahashi K; Oku T; Suzuki M; Higashi K; Adachi H; Nishimura Y; Nakajima M; Irimura T; Higashi N
Int J Mol Sci; 2024 Jun; 25(11):. PubMed ID: 38892469
[TBL] [Abstract][Full Text] [Related]
5. 3-O sulfation of syndecan-1 mediated by the sulfotransferase HS3ST3a1 enhances myeloma aggressiveness.
Baert L; Manfroi B; Quintero M; Chavarria O; Barbon PV; Clement E; Zeller A; Van Kuppevelt T; Sturm N; Moreaux J; Tveita A; Bogen B; McKee T; Huard B
Matrix Biol; 2023 Jun; 120():60-75. PubMed ID: 37201729
[TBL] [Abstract][Full Text] [Related]
6. Heparanase-enhanced Shedding of Syndecan-1 and Its Role in Driving Disease Pathogenesis and Progression.
Rangarajan S; Richter JR; Richter RP; Bandari SK; Tripathi K; Vlodavsky I; Sanderson RD
J Histochem Cytochem; 2020 Dec; 68(12):823-840. PubMed ID: 32623935
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy stimulates syndecan-1 shedding: a potentially negative effect of treatment that may promote tumor relapse.
Ramani VC; Sanderson RD
Matrix Biol; 2014 Apr; 35():215-22. PubMed ID: 24145151
[TBL] [Abstract][Full Text] [Related]
8. Targeted therapy for multiple myeloma: an overview on CD138-based strategies.
Riccardi F; Tangredi C; Dal Bo M; Toffoli G
Front Oncol; 2024; 14():1370854. PubMed ID: 38655136
[TBL] [Abstract][Full Text] [Related]
9. Heparanase inhibitor OGT 2115 induces prostate cancer cell apoptosis via the downregulation of MCL‑1.
Li X; Xu SJ; Jin B; Lu HS; Zhao SK; Ding XF; Xu LL; Li HJ; Liu SC; Chen J; Chen G
Oncol Lett; 2024 Feb; 27(2):83. PubMed ID: 38249815
[TBL] [Abstract][Full Text] [Related]
10. Targeting syndecan-1: new opportunities in cancer therapy.
Yang Z; Chen S; Ying H; Yao W
Am J Physiol Cell Physiol; 2022 Jul; 323(1):C29-C45. PubMed ID: 35584326
[TBL] [Abstract][Full Text] [Related]
11. Heparan Sulfate Glycosaminoglycans: (Un)Expected Allies in Cancer Clinical Management.
Faria-Ramos I; Poças J; Marques C; Santos-Antunes J; Macedo G; Reis CA; Magalhães A
Biomolecules; 2021 Jan; 11(2):. PubMed ID: 33494442
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-1252-5p Associated with Extracellular Vesicles Enhances Bortezomib Sensitivity in Multiple Myeloma Cells by Targeting Heparanase.
Rodrigues-Junior DM; Pelarin MFA; Nader HB; Vettore AL; Pinhal MAS
Onco Targets Ther; 2021; 14():455-467. PubMed ID: 33488100
[TBL] [Abstract][Full Text] [Related]
13. Interplay between Cell-Surface Receptors and Extracellular Matrix in Skin.
Kleiser S; Nyström A
Biomolecules; 2020 Aug; 10(8):. PubMed ID: 32796709
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy With Immunoconjugates for Multiple Myeloma.
Bruins WSC; Zweegman S; Mutis T; van de Donk NWCJ
Front Immunol; 2020; 11():1155. PubMed ID: 32636838
[TBL] [Abstract][Full Text] [Related]
15. Sirtuin 1 and endothelial glycocalyx.
Lipphardt M; Song JW; Goligorsky MS
Pflugers Arch; 2020 Aug; 472(8):991-1002. PubMed ID: 32494847
[TBL] [Abstract][Full Text] [Related]
16. Syndecan-1-Dependent Regulation of Heparanase Affects Invasiveness, Stem Cell Properties, and Therapeutic Resistance of Caco2 Colon Cancer Cells.
Katakam SK; Pelucchi P; Cocola C; Reinbold R; Vlodavsky I; Greve B; Götte M
Front Oncol; 2020; 10():774. PubMed ID: 32477959
[TBL] [Abstract][Full Text] [Related]
17. Heparanase: A Dynamic Promoter of Myeloma Progression.
Purushothaman A; Sanderson RD
Adv Exp Med Biol; 2020; 1221():331-349. PubMed ID: 32274716
[TBL] [Abstract][Full Text] [Related]
18. Forty Years of Basic and Translational Heparanase Research.
Vlodavsky I; Ilan N; Sanderson RD
Adv Exp Med Biol; 2020; 1221():3-59. PubMed ID: 32274705
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment-Associated Extracellular Matrix Components Regulate NK Cell Function.
Rossi GR; Trindade ES; Souza-Fonseca-Guimaraes F
Front Immunol; 2020; 11():73. PubMed ID: 32063906
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
